°í·Á´ëÇб³ ±¸·Îº´¿ø

°í·Á´ëÇб³ ±¸·Îº´¿ø


ºñ±Þ¿©Áø·áºñ¿ë

  • HOME
  • ÀÌ¿ë¾È³»
  • Áø·á¾È³»
  • ºñ±Þ¿©Áø·áºñ¿ë
  • ÇàÀ§
È®´ë Ãà¼Ò

ÀÇ·á¹ý Á¦45Á¶ ¹× µ¿¹ý ½ÃÇà±ÔÄ¢ Á¦42Á¶ÀÇ 2¿¡ ÀÇÇÑ ºñ±Þ¿© Áø·áºñ¿ë °íÁö
±âÁØÀÏ : 2023.01

ºñ±Þ¿©Áø·áºñ¿ë ÇàÀ§ ¸ñ·Ï
Áߺзù ¼ÒºÐ·ù Ç× ¸ñ Áø·áºñ¿ë µî(´ÜÀ§: ¿ø) ƯÀÌ
»çÇ×
ÃÖÁ¾
º¯°æÀÏ
ÄÚµå ¸íĪ ±¸ºÐ ºñ¿ë ÃÖÀúºñ¿ë ÃÖ°íºñ¿ë Ä¡·á
Àç·á´ë
Æ÷ÇÔ
¿©ºÎ
¾àÁ¦ºñ
Æ÷ÇÔ
¿©ºÎ
°Ë»ç·á ºÐÀÚº´¸®°Ë»ç CMT1A, PMP22 Gene Mutation(MLPA) CMT1A, PMP22 Gene Mutation(MLPA) 423,500 À§Å¹ 2023.1.1.
°Ë»ç·á ºÐÀÚº´¸®°Ë»ç Ä£ÀÚ°¨º°(Ãß°¡) Ä£ÀÚ°¨º°(Ãß°¡) 325,720 Ãß°¡, À§Å¹ 2023.1.1.
°Ë»ç·á ºÐÀÚº´¸®°Ë»ç ¾×ü»ý°Ë µ¹¿¬º¯ÀÌ ÇÁ·ÎÆÄÀϸµ[Guardant360 Liquid Biopsy(NGS)] ¾×ü»ý°Ë µ¹¿¬º¯ÀÌ ÇÁ·ÎÆÄÀϸµ[Guardant360 Liquid Biopsy(NGS)] 3,993,000 ±¹¿ÜÀ§Å¹ 2023.1.1.
°Ë»ç·á ºÐÀÚ»ý¹°°Ë»ç SARS-Cov2 °£º´ÀÎ,º¸È£ÀÚ ±×·ì°Ë»ç SARS-Cov2 °£º´ÀÎ,º¸È£ÀÚ ±×·ì°Ë»ç 35,820 2023.1.1.
°Ë»ç·á »ý½Ä±â±â´É°Ë»ç À½°æ±â´É°Ë»ç(¾ß°£)NPT À½°æ±â´É°Ë»ç(¾ß°£)NPT 335,000 ¾ß°£ 2023.1.1.
°Ë»ç·á »ý½Ä±â±â´É°Ë»ç À½°æ±â´É°Ë»ç(ÁÖ°£) À½°æ±â´É°Ë»ç(ÁÖ°£) 291,300 ÁÖ°£ 2023.1.1.
°Ë»ç·á »ý½Ä±â±â´É°Ë»ç Áøµ¿°¨°¢Áö°¢ÃøÁ¤±â ÀÌ¿ëÇÑ Á¶·ç°Ë»ç Áøµ¿°¨°¢Áö°¢ÃøÁ¤±â ÀÌ¿ëÇÑ Á¶·ç°Ë»ç 17,600 2023.1.1.
°Ë»ç·á »ý½Ä±â±â´É°Ë»ç Áøµ¿°¢ÃøÁ¤±â¸¦ ÀÌ¿ëÇÑ ¿µ»ó¹ß±â´É°Ë»ç Áøµ¿°¢ÃøÁ¤±â¸¦ ÀÌ¿ëÇÑ ¿µ»ó¹ß±â´É°Ë»ç 198,700 2023.1.1.
°Ë»ç·á »ý½Ä±â±â´É°Ë»ç Áú¾ÐÃøÁ¤ Áú¾ÐÃøÁ¤(GU) 33,800 ºñ´¢ÀÇÇаú 2023.1.1.
°Ë»ç·á ¼¼Æ÷¸é¿ª°Ë»ç ¾ç¼ö°Ë»ç ¾ç¼ö°Ë»ç FEE 598,000 2023.1.1.
ÃÖ±Ù ¸®½ºÆ® ÀÌÀü ¸®½ºÆ® 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ ¸®½ºÆ® ¸¶Áö¸· ¸®½ºÆ®
°Ë»ö

Quick ¸Þ´º

  • Áø·á½Ã°£Ç¥
  • ÀÇ·áÁø ã±â
  • Áø·á¿¹¾à
  • ÀüÈ­¹øÈ£ ã±â
  • ã¾Æ¿À½Ã´Â ±æ
  • °í°´ÀÇ ¼Ò¸®
  • Áø·á¿¹¾à¼¾ÅÍ - 1577-9966


°ü·Ã »çÀÌÆ® À̵¿ À̵¿ À̵¿ À̵¿ À̵¿ À̵¿

  • Áø·á°ú / ¼¾ÅÍ / Áø·áÁö¿øºÎ¼­
  • Æйи®»çÀÌÆ®